- Why in news
- On 3 September 2026, Union Minister Dr Jitendra Singh launched BIO-NIVESH, a platform linking biotechnology startups with investors, at a joint round table in New Delhi. BIRAC is the lead body behind it.
- What it is
- BIO-NIVESH is a recurring platform that brings biotechnology and deep-tech startups face to face with investors. It aims to move promising innovations from laboratory to scale and market using private capital. It is driven by BIRAC, the Department of Biotechnology's public sector arm for startup support.
- Purpose
- A strategic platform to strengthen engagement between biotech innovators and investors and channel private capital into scale-up and commercialisation.
- First edition
- 20 startups were selected on innovation, stage, market potential, scalability and regulatory readiness, and met around 50 investors.
- RDI Fund link
- BIRAC is a Second-Level Fund Manager for biotech and allied sectors under the ₹1 lakh crore Research, Development and Innovation Fund.
- Format
- It is meant to recur, with later editions in different cities.
- BIRAC
- BIRAC (Biotechnology Industry Research Assistance Council) is a not-for-profit public sector company set up by the Department of Biotechnology to support biotech startups and industry.
Don’t confuse with BIRAC vs DBT: DBT is the government department under the Ministry of Science & Technology. BIRAC is its enterprise-support company, which runs this platform.
Don’t confuse with RDI Fund vs BIO-NIVESH: The RDI Fund is a ₹1 lakh crore financing framework. BIO-NIVESH is an engagement platform that connects startups and investors.
Schemes: 52 Prelims questions since 2013, 10 in Prelims 2026 alone. They test features, the period and who funds it. In Mains, 33 news-triggered questions, mostly GS3.
Why it matters
- Helps close the gap between laboratory research and commercial scale in biotechnology, which needs long development cycles and heavy capital.
- Draws private capital to complement limited public funding and supports the growing bioeconomy.
Problems
- Biotech has long development cycles, demanding regulatory pathways and high capital needs, which deter investors.
- A platform of pitches and meetings may not convert into actual investments unless outcomes are tracked.
Way forward
- Judge the platform by partnerships, investments mobilised and products brought to market, not by the number of meetings.
- Use the RDI Fund and BIRAC to provide patient capital and de-risk early-stage projects.
Put in your answer
Catalytic role of government: Public funding cannot take every innovation to market; government support should reduce early-stage risk and make innovations investable.
- 2018Mains GS3 · Q15Reasons for biotechnology activity in India and benefits to biopharma
- 2026Mains GS3 · Q12How startups promote innovation and employment; challenges and measures to overcome them
- 2024Mains GS3 · Q5Why few patented life-science innovations get commercialized in India despite high filings
- 2003Prelims Q55Match persons like Kiran Mazumdar Shaw with their associated sectors
- 2026Prelims Q48Which statements about GenomeIndia Project, funded by DBT, are correct
UPSC’s own questions that come close to this issue, from our Prelims and Mains banks.
No practice question for this one; the card may still help an answer. Why: New platform linking biotech startups and investors, but the release has few concrete features, funding or legal facts for a question.
Worth revising until Prelims 2028: most news questions come within two years of the event.